Researchers at the University of California - Berkeley have identified a potential new obesity treatment: boosting how much energy the body burns rather than just suppressing appetite.
A New Approach to Weight Loss
While popular GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound achieve weight loss by cutting food intake—which can trigger muscle loss—this study focuses on increasing energy expenditure.
- The Molecule: Researchers tested TOFA, a compound first discovered in the 1970s.
- Dual Action: TOFA blocks lipid production while signaling cells to consume fat for fuel.
- 18% Energy Boost: In mouse models, it increased energy expenditure by up to 18% without affecting body temperature or physical activity.
Key Benefits
- Preserves Muscle: Mice lost significant body fat while maintaining lean muscle mass.
- Improves Health Indicators: The treatment lowered blood sugar, reduced triglycerides, and improved signs of fatty liver disease.
- Enhances GLP-1 Drugs: When combined with GLP-1 medications, TOFA produced stronger weight loss and glucose control than either treatment alone.
The Berkeley team has launched a startup, ReRx Therapeutics, to advance TOFA toward human clinical trials.
Source: Science Daily
